Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.
Weng DE, Masci PA, Radka SF, Jackson TE, Weiss PA, Ganapathi R, Elson PJ, Capra WB, Parker VP, Lockridge JA, Cowens JW, Usman N, Borden EC. Weng DE, et al. Among authors: lockridge ja. Mol Cancer Ther. 2005 Jun;4(6):948-55. doi: 10.1158/1535-7163.MCT-04-0210. Mol Cancer Ther. 2005. PMID: 15956252 Clinical Trial.
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Kobayashi H, Eckhardt SG, Lockridge JA, Rothenberg ML, Sandler AB, O'Bryant CL, Cooper W, Holden SN, Aitchison RD, Usman N, Wolin M, Basche ML. Kobayashi H, et al. Among authors: lockridge ja. Cancer Chemother Pharmacol. 2005 Oct;56(4):329-36. doi: 10.1007/s00280-004-0968-x. Epub 2005 May 20. Cancer Chemother Pharmacol. 2005. PMID: 15906031 Clinical Trial.
RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.
Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, Do DV, Reisen G, Lockridge JA, Short B, Guerciolini R, Nguyen QD; Sirna-027 Study Investigators. Kaiser PK, et al. Among authors: lockridge ja. Am J Ophthalmol. 2010 Jul;150(1):33-39.e2. doi: 10.1016/j.ajo.2010.02.006. Am J Ophthalmol. 2010. PMID: 20609706 Clinical Trial.
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.
Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Morrissey DV, et al. Among authors: lockridge ja. Nat Biotechnol. 2005 Aug;23(8):1002-7. doi: 10.1038/nbt1122. Epub 2005 Jul 24. Nat Biotechnol. 2005. PMID: 16041363 Free article.
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.
Ganesh S, Kim MJ, Lee J, Feng X, Ule K, Mahan A, Krishnan HS, Wang Z, Anzahaee MY, Singhal G, Korboukh I, Lockridge JA, Sanftner L, Rijnbrand R, Abrams M, Brown BD. Ganesh S, et al. Among authors: lockridge ja. Mol Ther. 2024 Jun 5;32(6):1895-1916. doi: 10.1016/j.ymthe.2024.03.035. Epub 2024 Mar 27. Mol Ther. 2024. PMID: 38549376 Free article.
12 results